SMEs

BioAscent provides a ‘centre of excellence’ for both compound management and hit characterisation within the EU Lead Factory. It is responsible for the aggregation, storage, inventory tracking and distribution of the EU Lead Factory Joint European Compound Library (JECL) and conducts hit picking to support follow-up studies and LC-MS compound quality control via its analytical chemistry group. The bioscience group at BioAscent also supports the EU Lead Factory’s hit characterisation activities and offers extensive knowledge of the drug discovery cycle over a wide range of target classes based on many years of experience in pharma, biotech and academic drug discovery.

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / MSD R&D site in Newhouse, Scotland, UK. BioAscent’s drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal chemistry, synthetic chemistry, and computational chemistry, all with access to a library of 125K lead-like compounds via Compound Cloud.

Its compound management services allow its customers to both save costs and accelerate their drug discovery.  Operating since 2005, our €20 million facility stores and manages customer libraries ranging in size from a few thousand to a few hundred thousand compounds in both liquid and solid formats.  BioAscent can support your key compound management activities including aggregation, storage, weighing, dissolution, plating, LC-MS analysis and distribution.

PROJECT LEADER
Dr Sylviane Boucharens

Compound Management Activities – Dr S. Boucharens

Hit Characterisation and confirmation – Dr S. McElroy

For more information visit www.bioascent.com

 



Founded in early 2005 by senior life-sciences managers with extensive drug discovery expertise, Edelris is a privately-owned research and services company. It offers innovative natural-product‐like collections of screening compounds (Keymical Collections™); 3D pharmacophoric‐rich “Smart Fragments”; proven Natural Product total synthesis and derivatization expertise; and efficient hit/lead optimization capabilities. The Keymical Collections™ and Smart Fragments are designed to interact highly favourably with biological systems, increasing the potential for viable hits. More than 50 original compound series from the Keymical Collections™ comprise 100‐1,000 molecules per family and represent a total of over 10,000 potential hits with an average purity of >95%. Edelris also has a collection of 1900 fragments for FBDD, enhanced with Smart Fragments. Its hit exploration/lead optimization service is supported by a chemoinformatics/molecular modelling platform. The company has worked on several complex NP targets originally obtained from fermentation, either by derivatization of the natural source or by multi‐step total synthesis from commercially available building blocks.

PROJECT LEADER
Jean-Yves Ortholand 
CEO

For more information visit www.edelris.com



MercachemSyncom is the leading mid-sized European drug-discovery Contract Research Organization for solving your chemistry challenges, from the design and synthesis of small to medium-sized molecule hits, to the delivery of first GMP batches of identified clinical candidates. For over 25 years we blend vast scientific knowledge with inventiveness to make great leaps on your behalf. Over the years the library synthesis team has developed a vast toolbox for increased chemical space coverage and optimized their workflow for the client’s needs. With the collective knowledge of 300 drug discovery FTE we go further to unlock new potential.

PROJECT LEADERS
Dr Frank Leemhuis and Dr Ton Vries
Managing Directors

For more information visit www.mercachemsyncom.com


Pivot Park Screening Centre (PPSC) provides services in the field of assay aevelopment, lab automation, (ultra) High Throughput Screening (u-HTS) and hit-to-lead activities to find new leads for drug development. The screening facility includes state-of-the-art robotic facilities and an extensive collection of about 300,000 high quality drug-like compounds. PPSC supports pharma, SME’s and academia to optimize their drug discovery process with more efficient processes and quick and accurate results. Established in 2012 as a spin-off from Organon/MSD, the Pivot Park Screening Centre uses a new, open approach to build on the long-established history of screening in Oss. Also the screening of compounds for the European Lead Factory takes place at the PPSC facilities, placing our facilities at the heart of EU Lead Factory.

PPSC is part of, and located at Pivot Park, an inspiring campus for biopharmaceutical drug development. Pivot Park is one of Europe’s foremost biopharmaceutical innovation hubs. Located in the Netherlands, we offer world-class biopharmaceutical R&D facilities and a lively biopharma based knowledge community.

PROJECT LEADER 
Dr Steven van Helden

For more information visit www.pivotparkscreeningcentre.com


Sygnature Discovery is a leading independent provider of integrated drug discovery and pre-clinical resource and expertise offering fully integrated discovery project support, as well as discipline specific support in chemistry, computational sciences, bioscience, DMPK or physical sciences as needed by our clients. Sygnature undertake target validation, hit identification, hit-to-lead and lead optimisation projects as well as complete drug discovery programs.  Since 2011, 28 compounds discovered by Sygnature for clients have entered pre-clinical development and so far, 14 of these have progressed to clinical trials (Phases I, II and III).  

PROJECT LEADER
Dr Geraint Jones
Director of Chemistry

For more information visit www.sygnaturediscovery.com


Taros is a privately-owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization.

Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production. Since 2013 Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory and will be also in the lead of its recent continuation funded with EUR 36.5 million. Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.

PROJECT LEADER
Dr Dimitrios Tzalis
CEO. Member of EU Lead Factory Project Executive and Head of Chemistry

For more information visit www.tarosdiscovery.com

 


Former Partners

ARTTIC assists clients from all business and research sectors, small and large, private and public, to ensure the success of their collaborative research and innovation ventures. During close to 30 years of success, ARTTIC developed and demonstrated expertise in the set-up and management of more than 300 large-scale ambitious projects. Based on its long-standing experience in a range of funding programmes across scientific and technological domains, ARTTIC helps clients to move from strategic plans to effective competitive research and development of innovative solutions, resulting in successful applications and high-performance businesses.

Founded in Paris in 1987, ARTTIC is now a group of companies with main offices in France (Paris and Toulouse), Germany (Munich and Berlin), Belgium (Brussels), England (Derby) and Israel (Tel Aviv). In 2015, ARTTIC has been ranked first SME in Europe by the European Commission considering the number of grant agreements signed by ARTTIC.

PROJECT LEADER
Dr Claudia Pfander
Project Manager

For more information visit www.arttic.eu



ChemAxon is a leading global cheminformatics company, which provides web-enabled software applications and toolkits for chemists and biologists, among others. This software enables structure visualization and management, property predictions and calculations, virtual synthesis, screening, clustering and drug design. Within the EU Lead Factory project, ChemAxon has been building a portal to support crowd-sourcing using its core JChem Base and Marvin components. Scientific decisions taken while selecting successful proposals are supported by ChemAxon’s Discovery Toolkit, including various fingerprints and physico-chemical property predictors. The portal also gives submitters a way to keep track of their submission’s status and for the consortium’s selection committee to score and analyze submitted proposals. 

PROJECT LEADER 
Mr Mihaly Medzihradszky

For more information visit www.chemaxon.com



The Lead Discovery Center (LDC) aims to accelerate the professional translation of excellent basic research into innovative therapies for diseases with high medical need. Early stage projects from academia are transformed into innovative pharmaceutical leads that reach initial proof-of-concept in animals, with a focus on small molecules. Fostering pre-competitive collaborations as well as exchange with industry LDC sustains a preferred partnership with the Max Planck Society and has established alliances with AstraZeneca, Bayer, Daiichi-Sankyo, Merck, and Qurient as well as leading academic drug discovery centers around the globe. Core expertise includes cellular biology, assay development & screening, pharmacology and medicinal chemistry. LDC brings its industry-standard cheminformatics and medicinal chemistry expertise to the EU Lead Factory for the design of the novel Public Compound Collection. 

PROJECT LEADER
Dr Peter Nussbaumer
Managing Director

For more information visit www.lead-discovery.de